SpyGlass Pharma, Inc. Common Stock

SGP

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$26.17

−$0.34 · -1.28%

Aug 24, 10:10 AM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

41/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

Expensive

Momentum

Neutral

Sentiment

Mixed

Risk resilience

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Patrick H. Mooney
Listed since: Feb 6, 2026
Employees: 76

Market position

Day range

Current $26.17

$25.97$26.59

52-week range

Current $26.17

$17.06$32.44

Open: $26.48
Previous close: $26.51
Volume: 4.22K; 0.04× average
Average volume: 96.98K; Average daily volume
Market cap: 874.95M USD
Beta: -1.01; Market reference 1
50-day average: $21.6852; +20.68% above average
200-day average: $23.3259; +12.19% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM): -15.77×
P/B (TTM): 3.77×
P/S (TTM): 0×
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 0.00%
Operating margin: 0.00%
Net margin: 0.00%

Financial health

Debt / equity: 0.01×

Financial statements

Metric (USD)	FY2025
Cost of goods sold	612K USD
Gross profit	−612K USD
Research and development	28.64M USD
Selling, general, and administrative	12.2M USD
Operating expenses	40.84M USD
Interest income	3.11M USD
Depreciation and amortization	612K USD
Operating income	−41.45M USD
Net income	−39.87M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$50.50

92.97% upside

Past 12 months12-month forecastHigh $62.00Average $50.50Low $39.00

SGP news

247wallst.comAug 14, 2026

Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More

Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names like Wayfair, Roku, and Fox Corporation, while cooler inflation data reshuffled bets across stocks, bonds, oil, and…

Read source

globenewswire.comAug 6, 2026

SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027. Bimatoprost-Drug Ring System (BIM-DRS)…

Read source

defenseworld.netJul 26, 2026

Spyglass Pharma (NASDAQ:SGP) Shares Gap Up – Still a Buy?

Spyglass Pharma, Inc. (NASDAQ: SGP - Get Free Report)'s stock price gapped up prior to trading on Friday. The stock had previously closed at $20.88, but opened at $21.80. Spyglass Pharma shares last traded at $21.2550,…

Read source

defenseworld.netJul 25, 2026

Affinity Asset Advisors LLC Buys Shares of 250,000 Spyglass Pharma, Inc. $SGP

Affinity Asset Advisors LLC purchased a new position in shares of Spyglass Pharma, Inc. (NASDAQ: SGP) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission…

Read source

globenewswire.comJun 15, 2026

SpyGlass Pharma Appoints Shannon Treviño as General Counsel

ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of Shannon Treviño as…

Read source

globenewswire.comJun 2, 2026

SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing

ALISO VIEJO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced the appointment of Mike Pinder as vice president,…

Read source